RGNX vs. TARS, ETNB, SDGR, JANX, VERA, TVTX, EWTX, EVO, BHVN, and MESO
Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Tarsus Pharmaceuticals (TARS), 89BIO (ETNB), Schrodinger (SDGR), Janux Therapeutics (JANX), Vera Therapeutics (VERA), Travere Therapeutics (TVTX), Edgewise Therapeutics (EWTX), Evotec (EVO), Biohaven (BHVN), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry.
REGENXBIO vs. Its Competitors
REGENXBIO (NASDAQ:RGNX) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.
In the previous week, Tarsus Pharmaceuticals had 12 more articles in the media than REGENXBIO. MarketBeat recorded 15 mentions for Tarsus Pharmaceuticals and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.00 beat Tarsus Pharmaceuticals' score of -0.20 indicating that REGENXBIO is being referred to more favorably in the media.
REGENXBIO has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.
Tarsus Pharmaceuticals has higher revenue and earnings than REGENXBIO. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
Tarsus Pharmaceuticals has a net margin of -44.91% compared to REGENXBIO's net margin of -100.62%. Tarsus Pharmaceuticals' return on equity of -39.72% beat REGENXBIO's return on equity.
88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 12.8% of REGENXBIO shares are held by company insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
REGENXBIO presently has a consensus price target of $31.63, indicating a potential upside of 267.90%. Tarsus Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 58.62%. Given REGENXBIO's higher probable upside, equities research analysts clearly believe REGENXBIO is more favorable than Tarsus Pharmaceuticals.
Summary
Tarsus Pharmaceuticals beats REGENXBIO on 11 of the 16 factors compared between the two stocks.
Get REGENXBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
REGENXBIO Competitors List
Related Companies and Tools
This page (NASDAQ:RGNX) was last updated on 7/21/2025 by MarketBeat.com Staff
Free RGNX Stock Alerts